Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Liu, Hao Li ^a   Huang, Chiung Yin ^b   Chen, Ju Yu ^a   Wang, Hay Yan Jack ^c   Chen, Pin Yuan ^b   Wei, Kuo Chen ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG UPTAKE; FOCUSED ULTRASOUND; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; MICROBUBBLE; MOUSE; NONHUMAN; PHARMACODYNAMICS; THERAPY EFFECT; TUMOR GROWTH; ULTRASOUND THERAPY; ULTRASOUND TRANSDUCER; ANALOGS AND DERIVATIVES; ANIMAL; CAPILLARY; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; PROCEDURES; SURVIVAL; TIGHT JUNCTION; TUMOR CELL LINE; TUMOR VOLUME; ULTRASOUND; VASCULARIZATION;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CAPILLARIES; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DACARBAZINE; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; MALE; MICE; MICROBUBBLES; SURVIVAL ANALYSIS; TIGHT JUNCTIONS; TUMOR BURDEN; ULTRASONICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916888712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114311     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
2. Galanis E, Buckner J (2000) Chemotherapy for high-grade gliomas. Br J Cancer 82:1371-1380.
3. Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635-644.
4. Kim H, Likhari P, Parker D, Statkevich P, Marco A, et al. (2001) High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 24:461-468.
5. Kim HK, Lin CC, Parker D, Veals J, Lim J, et al. (1997) High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl 703:225-233.
6. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, et al. (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309-317.
7. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.
8. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
9. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640-646.
10. Burger PC (1987) The anatomy of astrocytomas. Mayo Clin Proc 62:527-529.
11. Halperin EC, Burger PC, Bullard DE (1988) The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys 15:505-509.
12. Ewing JR, Brown SL, Lu M, Panda S, Ding G, et al. (2006) Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9 L model of rat cerebral tumor. J Cereb Blood Flow Metab 26:310-320.
13. Groothuis DR, Fischer JM, Lapin G, Bigner DD, Vick NA (1982) Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol 41:164-185.
14. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP (1982) Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the bloodbrain barrier. Proc Natl Acad Sci U S A 79:4420-4423.
15. Neuwelt EA, Frenkel EP, Gumerlock MK, Braziel R, Dana B, et al. (1986) Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series. Cancer 58:1609-1620.
16. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, et al. (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485-1491.
17. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N (2005) Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24:12-20.
18. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2003) Non-invasive opening of BBB by focused ultrasound. Acta Neurochir Suppl 86:555-558.
19. McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K (2005) MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol 31:1527-1537.
20. Mesiwala AH, Farrell L, Wenzel HJ, Silbergeld DL, Crum LA, et al. (2002) High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol 28:389-400.
21. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, et al. (1986) Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573-582.
22. Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, et al. (2010) Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 255:415-425.
23. Wei KC, Chu PC, Wang HY, Huang CY, Chen PY, et al. (2013) Focused ultrasound-induced bloodbrain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS One 8:e58995.
24. Reyderman L, Statkevich P, Thonoor CM, Patrick J, Batra VK, et al. (2004) Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 34:487-500.
25. Portnow J, Badie B, Chen M, Liu A, Blanchard S, et al. (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:7092-7098.
26. Figg WD, McLeod HL (2004) Handbook of anticancer pharmacokinetics and pharmacodynamics. Totowa, N. J.: Humana Press. xiv, 623 p. p.
27. Neuwelt EA, Frenkel EP, D'Agostino AN (1985) Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 45:2827-2833.
28. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051.
29. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollax J, et al. (1995) Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl 667:291-300.
30. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, et al. (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17:2604-2613.
31. Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton KB (1999) An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma. J Pharm Biomed Anal 19:659-668.
32. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, et al. (2002) Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43:1667-1673.
33. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, et al. (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5, 1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one (CCRG81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852.
34. Gupta V, Su YS, Wang W, Kardosh A, Liebes LF, et al. (2006) Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus 20:E20.
35. Hassouna I, Sperling S, Kim E, Schulz-Schaeffer W, Rave-Frank M, et al. (2008) Erythropoietin augments survival of glioma cells after radiation and temozolomide. Int J Radiat Oncol Biol Phys 72:927-934.